Navigation Links
Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
Date:2/1/2011

ROCKVILLE, Md., Feb. 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2010, on Thursday, February 10, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, February 10, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.The teleconference dial-in numbers are as follows:Domestic callers 1-800-591-6942International callers 1-617-614-4909Participant Passcode 43128562The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, February 10, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, February 17, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 66575807.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
2. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
3. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals Reports First Quarter 2009 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
9. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
10. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
11. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)...  Imanis Life Sciences announced today the launch ... viruses for virotherapy research. These viruses are licensed ... vaccinia virus-based technology platform for research use. ... partnership with Genelux to offer researchers, for the ... in research," said Dr. Kah Whye Peng ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... during the 12th annual Inventors Recognition Reception at Purdue Research Park ... a faculty member in recognition of outstanding contributions to, and success with, commercializing ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):